Fig. 3From: Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registryChanges in disease activity between the D2T RA and non-D2T RA groups. A DAS28-ESR, B DAS28-CRP, C SDAI, D CDAI, E RAPID3, F ACR20, G ACR50, and H ACR70Back to article page